Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KAZN antisense RNA 1 (KAZN-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the KAZN gene in Homo sapiens[1][3]. Antisense lncRNAs like KAZN-AS1 are known to regulate gene expression at multiple levels, including via epigenetic mechanisms and transcriptional interference, often acting in cis to regulate the expression of their sense gene counterparts[2][5]. While the broader class of antisense lncRNAs may be involved in critical cellular processes such as development, carcinogenesis, and responses to external stimuli, and are under investigation as potential therapeutic targets or biomarkers, there are currently no published reports confirming specific biological functions, disease associations, or drug targeting relevant solely to KAZN-AS1.
N/A for drugs, as no direct interacting drugs identified. General antisense lncRNA mechanisms include: Modulation of mRNA stability or translation; Chromatin remodeling; Transcriptional repression or activation in cis or trans[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KAZN antisense RNA 1 (KAZN-AS1).